Slide 1: Half-Year Results
HALF-YEAR RESULTS P. SEPTEMBER 8TH 2016
Slide 2: Presenters on the Call
2016 HALF-YEAR RESULTS PRESENTERS ON THE CALL Hervé BRAILLY Pierre DODION Catherine MOUKHEIBIR Nicolaï WAGTMANN CEO and co-founder Chief Medical Officer Senior Advisor Finance Chief Scientific Officer Page 2
Slide 3: Forward Looking Statement
FORWARD LOOKING STATEMENT This document has been prepared by Innate warranty or undertaking, express or implied, is Pharma S.A. (the “Company”) solely for the made as to, and no reliance should be placed on, purposes of a presentation to investors the fairness, accuracy, completeness or concerning t
Slide 4: Innate Pharma at a Glance
INNATE PHARMA AT A GLANCE Differentiated Science • Pioneer in the discovery and development of checkpoint in Immuno-Oncology inhibitors to activate the innate immune system • 3 clinical-stage candidates addressing novel targets, Portfolio of First-in-Class including two checkpoint inhibitors Antibod
Slide 5: Strategy to Become a Commercial Stage Biopharmaceutical Company
STRATEGY TO BECOME A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY R&D collaboration Global Co-development and Commercialization In-House Development 2003 - 2009 Monalizumab (Ph II) of IPH4102 • Testing in multiple indications • Retain full development and • Pursue single-agent & combination therapies
Slide 6: 1H16 Key Highlights
1H16 KEY HIGHLIGHTS • Continued progress with key clinical trials > First data for all three clinical programs expected before the end of 2016, including lirilumab > Fifth clinical trial of monalizumab program initiated; conducted by AstraZeneca, this trial is testing monalizumab in combination with
Slide 7: Pipeline as at September 8th, 2016
PIPELINE AS AT SEPTEMBER 8TH, 2016 PROGRAM TARGET INDICATION STAGE Lirilumab Acute Myeloid Leukemia - Single agent Phase II Licensed to KIR2DL1,2,3 Bristol-Myers Squibb Solid and hematological tumors - Multiple combinations 6 Phase I & II trials 0 Monalizumab Solid and hematological tumors - Single
Slide 8: Clinical Update
CLINICAL UPDATE
Slide 9: Clinical Update: Lirilumab
CLINICAL UPDATE PIPELINE PROGRESS AND EXPANSION Lirilumab, anti-KIR, licensed to Bristol-Myers Squibb • 1H16: • EffiKIR: 6th DSMB recommended continuation without modification • Six ongoing Phase I and II trials testing lirilumab in combination in solid tumors and hematological malignancies Liriluma
Slide 10: Clinical Update: Monalizumab
CLINICAL UPDATE PIPELINE PROGRESS AND EXPANSION Monalizumab, anti-NKG2A, partnered with AstraZeneca • 1H16: • Start of Phase I clinical trial of monalizumab in combination with durvalumab • Extension of Phase I/II trial in ovarian cancer to include endometrial and cervical cancer Monalizumab upcomin
Slide 11: Clinical Update: IPH4102
CLINICAL UPDATE PIPELINE PROGRESS AND EXPANSION IPH4102, anti-KIR3DL2 • 1H16: • Ongoing Phase I trial: open label Phase I trial, multicenter study of IPH4102 in patients with relapsed/ refractory KIR3DL2+ cutaneous T-cell lymphomas IPH4102 upcoming newsflow • Safety and activity data • Preliminary c
Slide 12: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 13: First Half 2016 Financial Highlights
FIRST HALF 2016 FINANCIAL HIGHLIGHTS STRONG FINANCIAL POSITION Well capitalized with cash, cash equivalents, and financial assets* of €243.6 million at the end of 2Q16 In thousand euros (IFRS) June 30, 2016 Dec. 31, 2015 Cash, cash equivalents and financial instruments 243,597 273,704 Total assets 2
Slide 14: Share Capital
SHARE CAPITAL KEY FIGURES AND ANALYST COVERAGE • Listed on Euronext, IPO in November 2006 10.1% > Euronext Paris: FR0010331421 – IPH 8.2% 2.2% • Stock liquidity (in 2016) > Average daily trading volume >300,000 79.5% > 53.9m outstanding shares (55.7 fully diluted) • Analyst coverage: > Bryan Garnier
Slide 15: Conclusion
CONCLUSION
Slide 16: Significant Newsflow Expected in 2016-2017
SIGNIFICANT NEWSFLOW EXPECTED IN 2016-2017 KEY CATALYSTS • First data for all three clinical programs expected before the end of 2016 Analysis of the primary efficacy endpoint, leukemia-free survival, expected EffiKIR in H2 2016 Lirilumab Safety data for the combination of lirilumab with nivolumab o
Slide 17: Investment Highlights
INVESTMENT HIGHLIGHTS • Differentiated science in immuno-oncology • Portfolio of first-in-class antibodies • Partnerships with leading immuno-oncology companies Summary • Building foundations to become a commercial stage biopharmaceutical company • Strong financial position and management team to ex
Slide 18: Q&A
Q&A
Slide 19: Contact Investor Relations
CONTACT INVESTOR RELATIONS Laure-Hélène Mercier Sr Director, Investor relations investors@innate-pharma.com Tel: +33 (0)4 30 30 30 87